Science & Enterprise subscription

Follow us on Twitter

  • Wearers of Fitbit activity tracking devices now have the option of sharing their data with a large-scale precision… https://t.co/2tKDCzwGDq
    about 3 hours ago
  • New post on Science and Enterprise: Fitbit Devices Providing Precision Medicine Data https://t.co/6BoD4wI5lI #Science #Business
    about 3 hours ago
  • An alliance of research organizations is designing ways to cut the time needed to develop, test, and manufacture ne… https://t.co/8mnuBqb6q0
    about 7 hours ago
  • New post on Science and Enterprise: Consortium to Speed Vaccine Production https://t.co/uU6E9yjKR9 #Science #Business
    about 7 hours ago
  • New contributed post on Science and Enterprise: https://t.co/iwQvJe2XGc How Your Company Can Make a Positive Impact on the World
    about 10 hours ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Genome-Editing Company Raises $108 Million in IPO

Artist depiction of Cas9 protein editing a gene (Jennifer Doudna, University of California – Berkeley)

6 May 2016. Intellia Therapeutics, a developer of therapies based on genome editing, issued its initial public stock offering, raising $108 million. The Cambridge, Massachusetts enterprise, less than 2 years old, issued 6 million shares priced at $18.00. At . . . → Read More: Genome-Editing Company Raises $108 Million in IPO

Cancer Diagnostics Company Raises $12.3M in IPO

(A. Kotok)

18 March 2016. VolitionRx, a developer of blood tests that screen for cancer and other disorders, is raising some $12.3 million in its initial public stock offering. The Namur, Belgium company, listed on the New York Stock Exchange under the symbol VNRX, issued about 3.8 million shares of common stock priced at . . . → Read More: Cancer Diagnostics Company Raises $12.3M in IPO

Genome-Editing Company Raises $94 Million in IPO

(bfishadow, WikimediaCommons)

3 February 2016. Editas Medicine, developer of treatments for disease that harness editing of the human genome, is raising $94.4 million in its initial public stock offering. The company, trading on the Nasdaq exchange under the symbol EDIT, issued 5.9 million shares priced at $16.00. As of 12 noon on 3 February, . . . → Read More: Genome-Editing Company Raises $94 Million in IPO

Gene Therapy Company Raises $70 Million in IPO

(bfishadow, WikimediaCommons)

11 November 2015. Voyager Therapeutics, a company less that two years old developing gene therapies for central nervous system disorders is raising $70 million in its initial public stock offering. The Cambridge, Massachusetts enterprise, trading on the Nasdaq exchange (symbol: VYGR), offered 5 million shares yesterday at $14.00. Shares closed today at . . . → Read More: Gene Therapy Company Raises $70 Million in IPO

RNA Therapy Biotech Earns $44 Million in IPO

(bfishadow, WikimediaCommons)

1 October 2015. A biotechnology company developing therapies based on RNA, genetic material that sends signals to cells, raised $43.75 million in its initial public stock offering. Mirna Therapeutics Inc. in Austin, Texas issued 6.25 million shares today at $7.00, and trades on the Nasdaq exchange under the symbol MIRN. Its shares . . . → Read More: RNA Therapy Biotech Earns $44 Million in IPO

Synthetic Biology Company Raises $200 Million in IPO

(A. Kotok)

21 August 2015. Intrexon Corp., a company developing genomic solutions with synthetic biology, raised some $200 million in its initial public stock offering. The Germantown, Maryland enterprise issued 4,878,049 shares of common stock priced at $41.00, and traded on the New York Stock Exchange under the symbol XON. The company’s shares closed . . . → Read More: Synthetic Biology Company Raises $200 Million in IPO

Blood Disease Biotech Gains $120 Million in IPO

Red blood cells with sickle cell disease (NCATS.NIH.gov)

12 August 2015. Global Blood Therapeutics, a biotechnology company developing treatments for blood-related disorders, is raising $120 million in its initial public stock offering. The company, in South San Francisco, California and trading on the Nasdaq exchange under the symbol GBT, issued 6 million shares priced . . . → Read More: Blood Disease Biotech Gains $120 Million in IPO

Peanut Allergy Therapy Company Raises $160 Million in IPO

(National Institute of Food and Agriculture, USDA)

6 August 2015. Aimmune Therapeutics Inc., a developer of treatments for peanut and other food allergies, raised $160 million from its initial public stock offering, pricing its 10 million shares at $16.00. Shares in the Brisbane, California company trade on the Nasdaq exchange under the symbol AIMT. . . . → Read More: Peanut Allergy Therapy Company Raises $160 Million in IPO

Drug Delivery Biotech Raises $101.8 Million in IPO

(A. Kotok)

17 July 2015. Chiasma Inc., a biotechnology enterprise developing oral therapies to replace injected drugs, raised some $101.8 million in its initial public stock offering. The company — located in Newton, Massachusetts and Jerusalem, Israel — issued 6,365,000 shares at $16.00, and trades on the Nasdaq exchange under the symbol CHMA. Shares . . . → Read More: Drug Delivery Biotech Raises $101.8 Million in IPO

Rare Disease Therapy Company Raises $60 Million in IPO

(bfishadow, WikimediaCommons)

26 June 2015. Catabasis Pharmaceuticals Inc., a biotechnology company creating treatments for rare diseases and cholesterol-related disorders, is raising $60 million in its initial public stock offering, trading on the Nasdaq exchange under the symbol CATB. The Cambridge, Massachusetts enterprise yesterday priced its 5 million shares at $12.00, and as of 4:00 . . . → Read More: Rare Disease Therapy Company Raises $60 Million in IPO